Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9504	Companies
186509	Keywords
118744	Articles
99812	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 08/12/2024 at 16:05, 1 year 3 months ago

Jaguar Health to Host Investor Webcast on August 13th

Crofelemer Investor Webcast Cancer Therapy-related Diarrhea Phase 3 Trial Q2 Financials
BRIEF

published on 08/12/2024 at 16:05, 1 year 3 months ago

Jaguar Health organise un webcast pour les investisseurs le 13 août

Crofelemer Essai De Phase 3 Résultats Financiers Du Deuxième Trimestre Webcast Pour Les Investisseurs Diarrhée Liée Au Traitement Du Cancer
PRESS RELEASE

published on 08/12/2024 at 16:00, 1 year 3 months ago

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Jaguar Health plans crofelemer approval pathway for breast and lung cancer based on phase 3 results. Join the investor webcast on August 13, 2024, for financial & corporate updates

Crofelemer Investor Webcast FDA Approval Jaguar Health Phase 3 Results
BRIEF

published on 08/05/2024 at 16:23, 1 year 4 months ago

Jaguar Health to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer

Crofelemer Jaguar Health OnTarget Trial Breast Cancer Lung Cancer
BRIEF

published on 08/05/2024 at 16:23, 1 year 4 months ago

Jaguar Health va explorer la voie d'approbation du Crofelemer dans le traitement du cancer du sein et du poumon

Crofelemer Santé Jaguar Essai OnTarget Cancer Du Sein Cancer Du Poumon
PRESS RELEASE

published on 08/05/2024 at 16:18, 1 year 4 months ago

Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningf
Jaguar Health, Inc. issued a letter to shareholders regarding the upcoming webcast to review second-quarter earnings and clinical data from the recent phase 3 OnTarget trial of crofelemer for breast and lung cancer patients

Crofelemer Webcast Jaguar Health Breast Cancer Lung Cancer
BRIEF

published on 08/02/2024 at 16:05, 1 year 4 months ago

Elaine Elisabetsky, PhD, to Discuss Plant-Based Schizophrenia Treatments

Jaguar Health Magdalena Biosciences Schizophrenia Plant-based Medicine Ethnopharmacology
BRIEF

published on 08/02/2024 at 16:05, 1 year 4 months ago

Elaine Elisabetsky, PhD, discutera des traitements contre la schizophrénie à base de plantes

Magdalena Biosciences Schizophrénie Santé Jaguar Médecine À Base De Plantes Ethnopharmacologie
PRESS RELEASE

published on 08/02/2024 at 16:00, 1 year 4 months ago

Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Dr. Elisabetsky conducts research on plant-based medicines for mental health conditions. Jaguar out-licenses botanical drug for schizophrenia treatment to Magdalena Biosciences

Jaguar Health Magdalena Biosciences Schizophrenia Dr. Elisabetsky Plant-based Medicines
BRIEF

published on 06/26/2024 at 14:35, 1 year 5 months ago

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement

Crofelemer Jaguar Health Nasdaq Compliance OnTarget Trial Cancer Supportive Care

Accesswire

Published on 12/10/2025 at 17:30, 32 minutes ago

SMX: Industry Validation Becomes Industry Visibility
Published on 12/10/2025 at 16:20, 1 hour 42 minutes ago

SMX Moves Past Proof and Into the NAFRA Room Where Implementation Begins
Published on 12/10/2025 at 15:10, 2 hours 52 minutes ago

Nano One Closes $6.96 Million Overnight Marketed Offering
Published on 12/10/2025 at 15:00, 3 hours 2 minutes ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Published on 12/10/2025 at 14:35, 3 hours 27 minutes ago

DataMetrex Signs Definitive Agreement to Acquire Yuzu Payment Processing Solution From Firstpayment Inc.

View all ACCESSWIRE

EQS Group

Published on 12/10/2025 at 17:28, 33 minutes ago

Amundi Physical Metals plc: Final Terms
Published on 12/10/2025 at 17:25, 37 minutes ago

Amundi Physical Metals plc: UK Final Terms
Published on 12/10/2025 at 17:19, 43 minutes ago

Custodian Property Income REIT plc: Share Buyback
Published on 12/10/2025 at 16:27, 1 hour 34 minutes ago

EQS-Adhoc: PATRIZIA SE: PATRIZIA and investors agree on long-term extension of Dawonia's mandate and scheme for realisation of exit carry
Published on 12/10/2025 at 16:11, 1 hour 51 minutes ago

EQS-Adhoc: Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München: Munich Re announces new Ambition 2030 multi-year strategy and 2026 financial targets

Les Echos

Published on 12/10/2025 at 17:45, 17 minutes ago

Innelec : Nomination de Julien Peyrafitte en tant que Président du Directoire d’Innelec Multimedia.
Published on 12/10/2025 at 17:45, 17 minutes ago

Innelec : Résultats du 1 er semestre 2025/26.
Published on 12/10/2025 at 17:40, 22 minutes ago

Changes within Mersen’s Executive committee
Published on 12/10/2025 at 17:40, 22 minutes ago

Evolutions au sein du Comité Exécutif de Mersen
Published on 12/10/2025 at 08:00, 10 hours 2 minutes ago

Neoen delivers Western Downs Battery Stage 2 and launches Stage 3 in Queensland, Australia

View all LES ECHOS COMFI WIRE